03.28.14
GE Healthcare has unveiled an advanced positron emission tomography/ computed tomography (PET/CT) molecular imaging system, the Discovery IQ.
GE Healthcare claims the Discovery IQ PET/CT is 40 percent more affordable than currently available PET/CTs.
GE Healthcare developed the Discovery IQ with Indian nuclear medicine physicians and oncologists, investing $15 million into the system. The Discovery IQ PET/CT incorporates advanced early disease detection capabilities as well as measurements to understand patient's response to cancer treatment.
GE Healthcare, with the support of several Indian entrepreneurs over the past few years, built a network of cyclotrons to halve the investment required to set up a molecular imaging centre.
The Discovery IQ is built on a platform that is upgradable on site to meet the increasing demands of a hospital, the company claims. The product also is scalable to fit the needs of India's healthcare providers.
The Discovery IQ system features Q.Clear technology, which can provide up to two times improvement in PET quantitative accuracy (SUVmean) and up to two times improvement in image quality (signal-to-noise ratio). According to GE Healthcare, the reconstruction technology shows the advantage of full convergence PET imaging without any compromise between quantitation and image quality.
GE Healthcare South Asia Oncology director N. R. Balamurugan noted that the Discovery IQ PET/CT will help PET/CT to become an integral part of cancer care management for India's cancer centers.
"Clinicians will now have ready access to tools that will allow evidence based and cost effective treatment. Together with our customers, we are focused on improving access, quality and affordable cancer care for the patient," Balamurugan said.
GE Healthcare claims the Discovery IQ PET/CT is 40 percent more affordable than currently available PET/CTs.
GE Healthcare developed the Discovery IQ with Indian nuclear medicine physicians and oncologists, investing $15 million into the system. The Discovery IQ PET/CT incorporates advanced early disease detection capabilities as well as measurements to understand patient's response to cancer treatment.
GE Healthcare, with the support of several Indian entrepreneurs over the past few years, built a network of cyclotrons to halve the investment required to set up a molecular imaging centre.
The Discovery IQ is built on a platform that is upgradable on site to meet the increasing demands of a hospital, the company claims. The product also is scalable to fit the needs of India's healthcare providers.
The Discovery IQ system features Q.Clear technology, which can provide up to two times improvement in PET quantitative accuracy (SUVmean) and up to two times improvement in image quality (signal-to-noise ratio). According to GE Healthcare, the reconstruction technology shows the advantage of full convergence PET imaging without any compromise between quantitation and image quality.
GE Healthcare South Asia Oncology director N. R. Balamurugan noted that the Discovery IQ PET/CT will help PET/CT to become an integral part of cancer care management for India's cancer centers.
"Clinicians will now have ready access to tools that will allow evidence based and cost effective treatment. Together with our customers, we are focused on improving access, quality and affordable cancer care for the patient," Balamurugan said.